Abstract
Vertebrates differ greatly in responses to pro-inflammatory agonists such as bacterial lipopolysaccharide (LPS), complicating use of animal models to study human sepsis or inflammatory disorders. We compared transcriptomes of resting and LPS-exposed blood from six LPS-sensitive species (rabbit, pig, sheep, cow, chimpanzee, human) and four LPS-resilient species (mice, rats, baboon, rhesus), as well as plasma proteomes and lipidomes. Unexpectedly, at baseline, sensitive species already had enhanced expression of LPS-responsive genes relative to resilient species. After LPS stimulation, maximally different genes in resilient species included genes that detoxify LPS, diminish bacterial growth, discriminate sepsis from SIRS, and play roles in autophagy and apoptosis. The findings reveal the molecular landscape of species differences in inflammation, and may inform better selection of species for pre-clinical models.
One-Sentence Summary Fundamental differences are present in blood of humans, mice and other species that differ in sensitivity to inflammation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Defense Advanced Research Projects Agency 15-21-THoR-FP-007, Contract no W911NF-16C-0079 administered by the US ARMY (HSW). The resources of the Southwest National Primate Research Center are supported by NIH Grant P51-OD011133 and U42-OD010442 from the Office of Research Infrastructure Programs/Office of the Director (REL). Portions of this research performed in the Environmental Molecular Sciences Laboratory, a U. S. Department of Energy (DOE) Office of Biological and Environmental Research national scientific user facility located at Pacific Northwest National Laboratory (PNNL) in Richland, WA, were also supported by NIH NIGMS GM103493. PNNL is operated by Battelle for the DOE under Contract No. DE-AC05-76RLO 1830 (PMP). Computational research was partially supported by Open Medicine Foundation (WX).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Texas Health Science Center gave ethical approval for this work - #HSC20170139H
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵‡ Deceased
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Sequencing data has been submitted to GEO and will be released publicly on formal publication.
